Ann: Appointment of consulting Chief Scientific Officer, page-2

"Dr. Rick Kuntz appointed as consulting Chief Scientific Officer
Sunnyvale, California; 22 February 2023:

EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the
“Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to
announce that it has appointed Dr. Rick Kuntz as consulting Chief Scientific Officer.

Dr. Kuntz has a broad background and expertise in many different areas of healthcare. He previously served
as Senior Vice President, Chief Medical and Scientific Officer of Medtronic overseeing medical affairs, health
policy, reimbursement, clinical research activities and corporate technology. In addition, he was the Founder
and Chief Scientific Officer of the Harvard Research Institute (HCRI), a university-based contract research
organisation which coordinates National Institutes of Health (NIH) and clinical trials with the United States Food
and Drug Administration (FDA).

Over his career, Dr. Kuntz has directed numerous multicentre clinical trials and has authored more than 250
original publications. He graduated from Miami University and received his medical degree from Case Western
Reserve University School of Medicine. He also completed fellowships in cardiovascular diseases and
interventional cardiology at the Beth Israel Hospital and Harvard Medical School. He has received his Master
of Science and Biostatistics from the Harvard School of Public Health.
Allan Will, Chairman of EBR Systems said:

“We are extremely delighted to have Rick on board as our consulting Chief Scientific Officer. His experience
overseeing clinical trials, particularly within the cardiac rhythm management space is unparalleled. Rick will
provide invaluable advice and counsel as we progress through the final stages of our pivotal SOLVE-CRT trial
and regulatory activities.”

Dr. Rick Kuntz said:
“EBR Systems is a clear leader in innovation within the cardiac rhythm management space and it has a device
that can potentially takeover conventional methods as the first-in-line pacing device for heart failure patients. I
look forward to helping further the Company’s goals and am excited to work with a passionate team dedicated
to improving the lives of many patients.”

What an endorsement by someone who has clearly the expertise and experience with one of the BIG THREE pacemaker manufacturers!